Ocular Toxicity of Belantamab Mafodotin, an Oncological Perspective of Management in Relapsed and Refractory Multiple Myeloma

Wahab, Ahsan; Rafae, Abdul; Mushtaq, Kamran; Masood, Adeel; Ehsan, Hamid; Khakwani, Maria; Khan, Aqsa

doi:10.3389/fonc.2021.678634

Public

Ocular Toxicity of Belantamab Mafodotin, an Oncological Perspective of Management in Relapsed and Refractory Multiple Myeloma

Published in Frontiers in Oncology • May 11, 2021

Authors:

Ahsan Wahab

Abdul Rafae

Kamran Mushtaq

Abstract

Belantamab mafodotin (belamaf), an antibody-drug conjugate approved for the treatment of relapsed and refractory multiple myeloma (RRMM), is an anti B-cell maturation antigen (BCMA) agent. DREAMM-1, a first in-human trial of belamaf, reported several ocular toxicities requiring dose adjustments, dos...

Subject

Medicine

Toxicity

Adverse effect

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!